Regulus Therapeutics Inc. (NASDAQ:RGLS) Q3 2022 Earnings Conference Call November 10, 2022 5:00 PM ET
Company Participants
Crispina Calsada - CFO
Jay Hagan - President, CEO & Director
Denis Drygin - Chief Scientific Officer
Conference Call Participants
Whitney Ijem - Canaccord Genuity
Yanan Zhu - Wells Fargo Securities
Operator
Hello, and welcome to the Regulus Therapeutics Inc. Q3 2022 Earnings Conference Call. [Operator Instructions].
I would now like to turn the conference over to Chief Financial Officer, Cris Calsada. Please go ahead.
Crispina Calsada
Thank you, and good afternoon, and thank you for joining us to discuss Regulus Therapeutics third quarter 2022 financial results and corporate highlights. .
Joining me on today's call is Jay Hagan, President and Chief Executive Officer; and Dr. Denis Drygin, Chief Scientific Officer. Jay will provide opening remarks and share progress on our ADPKD program, and I will review the financial results before we open the line for questions.
Before we begin, I'd like to remind you that this call will contain forward-looking statements concerning Regulus Therapeutics future expectations, plans, prospects, corporate strategy and performance, which constitute forward-looking statements for the purposes of the safe harbor provision under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in our filings with the SEC.
In addition, any forward-looking statements represent our views only as of the date of this webcast and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligations to update such statements.
I will now turn the call over to Jay.
Jay Hagan
Thanks, Cris, and welcome, everyone, to our third quarter earnings call and business update. I'll begin with a general update on our ADPKD program. We continue to make progress in the clinic with RGLS8429. In September, we announced positive top line safety and PK data from our Phase I single ascending dose, or SAD, clinical trial of RGLS8429. RGLS8429 was well tolerated with no serious adverse events reported.
Among the 32 subjects treated with RGLS8429 or placebo, there were only 9 adverse events, all of which were mild, except one, a sinus infection, which was graded moderate in severity. In addition, importantly, preliminary results suggest that plasma exposure is approximately linear across the 4 dose levels tested and is similar to the PK data from the first generation compound RGLS4326.